Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $268.1 million.

  • Legend Biotech's Total Non-Current Liabilities fell 2313.72% to $268.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.1 million, marking a year-over-year decrease of 2313.72%. This contributed to the annual value of $352.0 million for FY2024, which is 757.76% down from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Total Non-Current Liabilities is $268.1 million, which was down 2313.72% from $388.9 million recorded in Q2 2025.
  • Legend Biotech's 5-year Total Non-Current Liabilities high stood at $388.9 million for Q2 2025, and its period low was $262860.0 during Q1 2021.
  • Its 5-year average for Total Non-Current Liabilities is $302.9 million, with a median of $324.5 million in 2023.
  • Per our database at Business Quant, Legend Biotech's Total Non-Current Liabilities skyrocketed by 14310284.56% in 2022 and then tumbled by 2313.72% in 2025.
  • Legend Biotech's Total Non-Current Liabilities (Quarter) stood at $124.3 million in 2021, then surged by 132.36% to $288.9 million in 2022, then soared by 31.83% to $380.8 million in 2023, then fell by 7.58% to $352.0 million in 2024, then fell by 23.82% to $268.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $268.1 million for Q3 2025, versus $388.9 million for Q2 2025 and $363.5 million for Q1 2025.